BACKGROUND: Previous studies have reported any prognostic impact of preoperative leukocytosis, anemia and thrombocytosis in non-small cell lung cancer (NSCLC). The significance of the combined use of these 3 abnormal blood cell counts was investigated. PATIENTS AND METHODS: Two hundred and eighty-nine consecutive NSCLC patients were reviewed retrospectively. RESULTS: The patients with leukocytosis, anemia and thrombocytosis had significantly worse prognosis. The 5-year survival of the patients with all three of these abnormal blood cell counts was 25.0%, which was significantly poorer compared with that of the patients without any of these abnormal cell counts (78.23%). The 5-year survival of the patients with 1 or 2 out of the three abnormal blood cell counts was an intermediate value. Both univariate and multivariate analyses indicated the independent prognostic impact of the use of these three abnormal blood cell counts combined. CONCLUSION: The use of leukocytosis, anemia and thrombocytosis combined might be useful for predicting the prognosis of NSCLC patients.
BACKGROUND: Previous studies have reported any prognostic impact of preoperative leukocytosis, anemia and thrombocytosis in non-small cell lung cancer (NSCLC). The significance of the combined use of these 3 abnormal blood cell counts was investigated. PATIENTS AND METHODS: Two hundred and eighty-nine consecutive NSCLCpatients were reviewed retrospectively. RESULTS: The patients with leukocytosis, anemia and thrombocytosis had significantly worse prognosis. The 5-year survival of the patients with all three of these abnormal blood cell counts was 25.0%, which was significantly poorer compared with that of the patients without any of these abnormal cell counts (78.23%). The 5-year survival of the patients with 1 or 2 out of the three abnormal blood cell counts was an intermediate value. Both univariate and multivariate analyses indicated the independent prognostic impact of the use of these three abnormal blood cell counts combined. CONCLUSION: The use of leukocytosis, anemia and thrombocytosis combined might be useful for predicting the prognosis of NSCLCpatients.
Authors: Nicole M Kuderer; Marek S Poniewierski; Eva Culakova; Gary H Lyman; Alok A Khorana; Ingrid Pabinger; Giancarlo Agnelli; Howard A Liebman; Eric Vicaut; Guy Meyer; Frances A Shepherd Journal: Oncologist Date: 2017-09-26
Authors: Audrey E Kam; Gopichand Pendurti; Umang H Shah; Mohammad H Ghalib; Imran Chaudhary; Jennifer Chuy; Lakshmi Rajdev; Andreas Kaubisch; Santiago Aparo; Ioannis Mantzaris; Sanjay Goel Journal: Invest New Drugs Date: 2018-10-12 Impact factor: 3.850
Authors: Juan P Cata; Cristina Gutierrez; Reza J Mehran; David Rice; Joseph Nates; Lei Feng; Andrea Rodriguez-Restrepo; Fernando Martinez; Gabriel Mena; Vijaya Gottumukkala Journal: Cancer Cell Microenviron Date: 2016
Authors: Aaron Denson; Nancy Burke; Georgine Wapinsky; Barbara Bertels; Tzu-Hua Juan; Jae Lee; Gregory M Springett; Jonathan R Strosberg; Richard D Kim; Dan M Sullivan; Amit Mahipal Journal: Am J Clin Oncol Date: 2018-02 Impact factor: 2.339
Authors: Georg Holgersson; Martin Sandelin; Even Hoye; Stefan Bergström; Roger Henriksson; Simon Ekman; Jan Nyman; Martin Helsing; Signe Friesland; Margareta Holgersson; Kristina Lamberg Lundström; Christer Janson; Elisabet Birath; Charlotte Mörth; Thomas Blystad; Sven-Börje Ewers; Britta Löden; Michael Bergqvist Journal: Med Oncol Date: 2012-05-08 Impact factor: 3.064